Please use this identifier to cite or link to this item:
Title: Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study
Authors: Lemos, Marcelo M. [UNIFESP]
Watanabe, Renato [UNIFESP]
Carvalho, Aluizio B. [UNIFESP]
Jancikic, Alessandra D. B. [UNIFESP]
Sanches, Fabiana M. R. [UNIFESP]
Christofalo, Dejaldo M. [UNIFESP]
Draibe, Sergio A. [UNIFESP]
Canziani, Maria Eugenia F. [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Keywords: vascular calcification
nondialysis patients
Issue Date: 1-Jul-2013
Publisher: Dustri-verlag Dr Karl Feistle
Citation: Clinical Nephrology. Deisenhofen-muenchen: Dustri-verlag Dr Karl Feistle, v. 80, n. 1, p. 1-8, 2013.
Abstract: Introduction: Coronary artery calcification (CAC) is highly prevalent among chronic kidney disease (CKD) patients and its strong association with mortality has been recognized early in the course of CKD. the aim of the present study was to test the effect of rosuvastatin and sevelamer hydrochloride on the progression of CAC in nondialyzed CKD patients. Methods: An open-label, randomized and controlled pilot study was conducted including 117 CKD patients (62% men, 56.9 +/- 11.2 years, eGFR 36 +/- 16.5 ml/min) Patients were randomly assigned to rosuvastatin (n = 38; 10 mg/day), to sevelamer hydrochloride (n = 38; 2,400 mg/day) and to control (n = 41) groups. CAC (by multislice computed tomography) and biochemical analyses were performed at baseline and after 24 months. Results: At baseline, CAC was observed in 55%, 58% and 61% of patients in the rosuvastatin, sevelamer hydrochloride and control groups, respectively (p = 0.87). Calcium score at baseline as well as its absolute and relative changes during 24 months were similar among the groups. Low density lipoprotein cholesterol (LDL-c) was higher and decreased significantly in the rosuvastatin group (p < 0.01). the analysis adjusting for LDL-c showed that the drug regimens were not associated with the progression of CAC (drug effect p = 0.85; time-effect p < 0.001; interaction p = 0.76). Conclusions: Treatment with rosuvastatin and sevelamer hydrochloride may not delay the progression of CAC in non-dialysis dependent CKD patients.
ISSN: 0301-0430
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.